BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
Phase 2
Terminated
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- Other: Placebo
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 124
- Registration Number
- NCT04267393
- Locations
- 🇺🇸
Local Institution - 0150, Baltimore, Maryland, United States
🇺🇸Local Institution - 0171, Dallas, Texas, United States
🇺🇸Local Institution - 0143, Redwood City, California, United States
A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 34
- Registration Number
- NCT04263350
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT04249284
- Locations
- 🇺🇸
Quotient Sciences Miami, Miami, Florida, United States
A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT04237831
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Prism Clinical Research, Saint Paul, Minnesota, United States
A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT04225936
- Locations
- 🇺🇸
The Texas Liver Institute, San Antonio, Texas, United States
A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT04209699
- Locations
- 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
Phase 3
Completed
- Conditions
- Bladder TumorMuscle-Invasive Bladder CancerBladder Cancer
- Interventions
- Biological: NivolumabProcedure: Radical cystectomy (RC)Biological: Bempegaldesleukin
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 114
- Registration Number
- NCT04209114
- Locations
- 🇩🇪
Local Institution - 0117, Duesseldorf, Germany
🇨🇦Local Institution - 0036, Sherbrooke, Quebec, Canada
🇨🇦Local Institution - 0082, Oshawa, Ontario, Canada
A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 10
- Registration Number
- NCT04196452
- Locations
- 🇺🇸
Local Institution, Princeton, New Jersey, United States
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Autoimmune DisorderRheumatoid ArthritisSystemic Lupus ErythematosusPrimary Sjögren's Syndrome
- Interventions
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 119
- Registration Number
- NCT04186871
- Locations
- 🇺🇸
Local Institution - 0083, Spokane, Washington, United States
🇺🇸Local Institution - 0024, Encino, California, United States
🇫🇷Local Institution - 0075, Brest, France
A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 171
- Registration Number
- NCT04175925
- Locations
- 🇺🇸
ICON (LPRA) - Lenexa, Lenexa, Kansas, United States
© Copyright 2025. All Rights Reserved by MedPath